Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|11|1695-1701

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.11, 2014-06, pp. : 1695-1701

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3826-3835

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite

The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

By  

CANCER, Vol. 120, Iss. 20, 2014-10 ,pp. : 3142-3153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib

By  

CANCER, Vol. 120, Iss. 4, 2014-02 ,pp. : 530-536

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2316-2324

John Wiley & Sons Inc

Access to resources Recommend Favorite